PUR 003

Drug Profile

PUR 003

Alternative Names: PUR003

Latest Information Update: 22 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pulmatrix
  • Class Antivirals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Influenza virus infections

Most Recent Events

  • 21 May 2012 Pharmacodynamics and tolerability data from a phase I trial in Asthma released by Pulmatrix
  • 15 Dec 2010 Pulmatrix receives grant from US Department of Defense for development of inhaled Cationic Airway Modulator (iCALM) products for infections
  • 27 Apr 2010 Pulmatrix completes a phase I trial in Healthy volunteers in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top